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Eﬃ  cacy of chlorhexidine application to umbilical cord on 
neonatal mortality in Pemba, Tanzania: a community-based 
randomised controlled trial
Sunil Sazawal, Usha Dhingra, Said M Ali, Arup Dutta, Saikat Deb, Shaali M Ame, Mkasha H Mkasha, Ashish Yadav, Robert E Black
Summary
Background In low-income countries, including the east African region, a third of neonatal deaths are due to 
infections. A substantial proportion of these have been attributed to sepsis, which can result from umbilical cord 
infections. Evidence from Asia suggests that chlorhexidine application to the neonatal umbilical cord reduces 
mortality, but no data from Africa are available. We aimed to assess the eﬀ ect of umbilical cord cleansing with 4% 
chlorhexidine solution on neonatal mortality and omphalitis in rural settings of sub-Saharan Africa.
Methods We did a community-based randomised controlled trial on Pemba Island, Zanzibar, Tanzania. All eligible 
babies (aged 1 h to 48 h, without congenital malformations) from hospital-based and community-based deliveries on 
Pemba Island were enrolled. Participants were randomly assigned to either 4% free chlorhexidine for cord care or to 
dry cord care using a computer-generated random sequence. For babies allocated to the chlorhexidine group, mothers 
or caretakers were advised to apply the solution to the cord every day until 3 days after the cord had dropped oﬀ . Cord 
stumps were examined for redness, pus, swelling, and foul odour on day 0, 1, 4, 10, and 28. The primary outcome for 
this study was mortality until day 28 on an intention-to-treat basis. The trial is registered with ClinicalTrials.gov, 
number NCT01528852.
Findings Between May 19, 2011, and Aug 31, 2014, 36 911 newborn babies were enrolled into the chlorhexidine 
(n=18 015) and dry cord care study (n=18 896) groups. 17 468 (96·9%) of 18 015 neonates in the chlorhexidine group 
were available for complete follow-up (28 days) compared with 18 384 (97·3%) of 18 896 neonates in the dry cord care 
group. Mortality rate in the chlorhexidine group (10·5 deaths per 1000 livebirths) was not signiﬁ cantly lower than that 
in the dry cord care group (11·7 per 1000 livebirths; relative risk 0·90, 0·74–1·09; p=0·27).
Interpretation Our ﬁ ndings do not support the use of chlorhexidine for reduction of neonatal mortality in this east 
African setting, which might not justify a change in the WHO policy. To inform global policy, a detailed meta-analysis 
and pooled analysis needs to be undertaken using data from both African and Asian settings.
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Introduction
Asia and sub-Saharan Africa have the highest neonatal 
mortality rates in the world (about 29 deaths per 
1000 livebirths),1 with about 50% of neonatal deaths 
occurring on the ﬁ rst day of life.2 Although post-
neonatal mortality rates have reduced substantially over 
the past 25 years, deaths in the neonatal period have 
decreased more slowly and now account for 47% of all 
deaths in children younger than 5 years.1 The worldwide 
neonatal mortality rate fell from 36 deaths (95% CI 
35–38) per 1000 livebirths in 1990 to 19 (95% CI 18–21) 
in 2015.1 Infections are estimated to be responsible for 
31·5% of these deaths between 2000 and 2015.3,4 
Neonatal sepsis aﬀ ects six to 21 babies per 
1000 livebirths, with a case-fatality rate of 27–56% 
leading to more than 336 357 deaths per year.3 
Percutaneous invasion of pathogens from umbilical 
cord infections has been postulated as a major cause of 
neonatal sepsis.5,6
Unsanitary conditions in delivery and care of newborn 
babies might contribute to the high rate of omphalitis and 
serious systemic infection.7 Approaches such as hygiene 
promotion (including handwashing related to delivery 
and neonatal care), intrapartum vaginal and neonate skin 
cleansing with antiseptics such as chlorhexidine, and use 
of clean birth kits have been implemented to reduce the 
risk of neonatal infections.8–10 Three clinical trials7,8,11 have 
provided evidence about the eﬀ ectiveness of chlorhexidine 
application to the neonatal umbilical cord in Asia, but no 
data from Africa exists. Current WHO guidelines12 
suggest application of chlorhexidine to the umbilical 
stump during the ﬁ rst week of life for babies born 
at home in settings with high neonatal mortality 
(≥30 neonatal deaths per 1000 livebirths) and to use dry 
cord care for newborn babies in settings with lower 
(<30 deaths per 1000 livebirths) neonatal mortality.
Chlorhexidine, a broad-spectrum topical antiseptic 
with strong residual activity, has been shown to be 
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eﬀ ective in reducing infections in the neonatal period.13 
Chlorhexidine is not expensive and, with a strong safety 
record, is a potential intervention in low-resource 
settings.14,15 Chlorhexidine is included in the WHO model 
list of essential medicines for children.16
All trial sites in the studies in south Asia7,8,11 had 
neonatal mortality rates of more than 35 deaths per 
1000 livebirths, and nearly all births took place at home. 
A WHO expert panel discussed the possible role of 
chlorhexidine for cord care in low-resource community 
settings and emphasised the need for more studies from 
south Asia, as well as the need for similar trials in 
Africa.17 In this community-based randomised trial, we 
aimed to investigate the eﬀ ect of umbilical cord 
cleansing with 4% chlorhexidine solution on the rates of 
neonatal mortality and omphalitis in a rural setting in 
Tanzania. A similar trial was started at the same time 
in Zambia, the results of which are also published in 
The Lancet Global Health.18
Methods
Study design
We did a community-based randomised controlled trial 
on Pemba Island in the Zanzibar archipelago oﬀ  the 
coast of east Africa, where the neonatal mortality rate 
was 25 deaths per 1000 livebirths and infant mortality 
rate was 89 deaths per 1000 livebirths.19 More than 99% of 
the population are Shirazi Muslims and reside in an 
estimated 70 000 households on the island. The literacy 
rate of the population is 52%, and the birth rate is 
8500–9000 births per year, about 40% of which take place 
at home (actual data collected during the study).19
The island has four district hospitals and a cottage 
hospital that provide outpatient and inpatient health 
services. At the community level, many government 
health centres provide basic maternal and child health 
(MCH) services. Other community-based health-care 
providers include trained or untrained traditional birth 
attendants (TBAs) at the village level and several over-the-
counter drug outlets and traditional healers.
The study protocol was reviewed and approved by the 
institutional review board of the Johns Hopkins 
Bloomberg School of Public Health, USA, and the 
Zanzibar Medical Research and Ethics Committee, 
Tanzania. A joint technical advisory group (TAG) and 
data safety monitoring board (DSMB) for the Zambia 
and Pemba trials were established prior to study 
implementation.
Participants
All newborn babies from 1 h to 48 h of age born in 
hospital or the community (home based) on Pemba 
Island between May 19, 2011, and Aug 31, 2014, were 
eligible for inclusion in the study. The mother or 
father of the newborn baby must have been a 
permanent resident of the island, and the parents (or a 
literate witness if the parents were illiterate) must 
have given written consent to participate in the trial. 
Newborn babies with any congenital malformations 
that prevented application of intervention and babies 
Research in context
Evidence before this study
We searched PubMed and the Cochrane Library with search terms 
“chlorhexidine”, “cord care”, “mortality”, and “omphalitis” for all 
articles published in English until November, 2015. Three trials 
from southeast Asia (Nepal, Bangladesh, and Pakistan) have 
reported the eﬀ ects of chlorhexidine on neonatal mortality and 
omphalitis. They reported signiﬁ cant eﬀ ects of chlorhexidine on 
reducing neonatal mortality, but some questions remain 
unanswered. The study in Bangladesh showed an eﬀ ect of 1 day 
treatment of chlorhexidine, but no eﬀ ect was observed with 
7 day treatment; the study in Nepal was not statistically 
signiﬁ cant for overall eﬀ ect; and the study in Pakistan presented 
a factorial analysis with a clinically important interaction 
(maternal handwashing and chlorhexidine application increased 
mortality by 17–18%). No data was available in an African setting 
for the eﬀ ect of chlorhexidine cord care on neonatal mortality. 
Additionally, all the previous studies were done in settings with 
neonatal mortality rate of 40 deaths per 1000 livebirths or 
higher and almost all births took place in the community.
Added value of this study
Two studies (done in Pemba and Zambia) were designed to 
bridge the knowledge gap. This study, done in Pemba and 
combined with the mortality results from Zambia, is the 
ﬁ rst to our knowledge to provide data on the eﬀ ect of 
chlorhexidine cord care on neonatal mortality and cord 
infections in an east African setting. Previous research did not 
address the issues raised by the WHO review about the eﬀ ects 
of chlorhexidine in settings with hospital-based deliveries of 
more than 40% and with neonatal mortality rate of less than 
30 deaths per 1000 livebirths. The study is unique in 
providing data on both omphalitis and neonatal mortality 
and showing a disconnect between a reduction in omphalitis 
and reduction in neonatal mortality, similar to the results of 
the Bangladesh study. 
Implications of all the available evidence
All the available data (three Asian and two African studies) 
need to be reviewed using common methods and a 
meaningful meta-analysis needs to be done to guide the 
policy for use of chlorhexidine cord care in Asia and Africa. 
The data from African settings provided by this study 
combined with the results from Zambia might alter the 
global policy consensus about chlorhexidine cord care. 
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who needed to be admitted to hospital were excluded 
from the study.
As part of the pre-trial preparation (formative research 
phase), all the TBAs on the island and MCH staﬀ  were 
contacted and trained in the study procedures. Two study 
supervisors were stationed at each of the maternity wards 
of all the four major hospitals in Pemba (in two shifts) to 
cover deliveries occurring from 0700 h to 2000 h. 
Additionally, staﬀ  nurses were hired on a temporary 
basis. After delivery, the study team (consisting of 
hospital staﬀ  and a study supervisor) screened each 
newborn baby for eligibility to participate in the study. If 
the baby was eligible and clinically stable, the study 
procedure and purpose was explained to the mother. 
This information was explained to the nearest kin and 
their consent to participate was sought if the mother was 
not stable or was deceased. Neonates were enrolled in the 
study after consent was obtained. For enrolment in the 
community, all TBAs were provided with a mobile phone. 
Whenever a delivery took place, a conference call between 
the TBA, study supervisor of that area, and MCH staﬀ  
was arranged to schedule a visit to the household. 
The study supervisor and MCH staﬀ  would then screen 
the newborn baby for eligibility and obtain consent 
accordingly.
Randomisation and masking
This study had two phases. During phase 1, participants 
were randomly assigned (1:1:1) to one of three intervention 
groups: treatment group using chlorhexidine, a control 
group using a placebo solution, and a control group with 
dry cord care. During phase 2 (Feb 20, 2013, onwards), the 
placebo solution was not used and the participants 
previously in that group were randomly assigned (1:1) to 
receive either chlorhexidine or dry cord care. This was 
done to facilitate combination of the ﬁ ndings with those 
from the Zambia trial (see Statistical analysis section). 
Randomisation was done using a computer-generated 
random sequence. The data for chlorhexidine and dry 
cord care groups from both phases of the study are 
presented in this Article. Other results from phase 1 will 
be presented in future papers.
For phase 1, chlorhexidine and placebo bottles were 
marked with 50 intervention codes (25 chlorhexidine and 
25 placebo) by an independent member of the DSMB, 
assisted by a team of temporary workers. Each enrolled 
newborn baby was randomly assigned (1:2) to either dry 
cord or wet cord care. For babies allocated to wet cord 
care, a second stage of random assignment allocated the 
baby to one of the 50 intervention codes. Based on the 
distribution of villages and health-care centres, the study 
area was divided into 25 working areas with a study 
supervisor assigned to each area. Each supervisor was 
provided with two sets of envelopes. The ﬁ rst set 
contained the randomisation code to allocate a baby to 
the dry or wet group, and the second set of envelopes 
contained the randomisation codes to allocate the baby to 
one of the 50 intervention (chlorhexidine or placebo) 
codes. At the hospital, random assignment to wet or dry 
cord care was done by day of enrolment so that all babies 
born on a particular day were allocated to either the wet 
cord care or dry cord care. The second set of envelopes 
were opened on the wet cord day only to allocate the child 
to one of the 50 intervention codes. During phase 2, a 
new list was generated by the DSMB statistician to 
randomly assign babies (1:1) into dry and chlorhexidine 
cord care groups. Implementation was changed slightly, 
because the second envelope was not needed. Masking of 
allocation of intervention to workers and participants 
during phase 2 was not possible because of the nature of 
the interventions.
Procedures
The intervention used in the study was a solution of 
chlorhexidine gluconate (4% free chlorhexidine; Galantic 
Pharma, Mumbai, India). Stability, potency, colour, 
odour, and consistency of the solution were tested at 
three stages of the preparation and also tested twice at 
the ﬁ eld site. As per the ﬁ ndings of our initial study 
comparing diﬀ erent modes of administration of 
chlorhexidine solution for cord cleaning,20 10 mL opaque 
dropper bottles were used for administration.
All babies in the trial had an initial examination, and 
neonatal care messages were relayed to the mother or 
caretaker. For babies allocated to the chlorhexidine group 
and the placebo group (in phase 1), the MCH worker 
showed the mother or caretaker how to apply the solution 
to the baby, gave 3 days supply of the solution, and 
instructed the mother or caretaker to apply the solution 
to the cord every day including 3 days after the cord had 
dropped oﬀ . The mother or caretaker was informed that 
the MCH worker would visit again on day 4 and day 10 to 
apply the solution. On day 4, the worker delivered six 
more bottles to the household. The MCH staﬀ  provided a 
date chart and a pen for the mother to mark the days on 
which she applied the solution. The mothers were 
requested to keep the bottles after use and the empty 
bottles were collected on subsequent visits. For babies 
assigned to the dry cord care group, in addition to the 
initial examination, data collection, and neonatal care 
messages, TBAs and hospital staﬀ  instructed the mothers 
and caretakers not to cleanse the umbilical cord stump 
and to keep it dry.
Each family was visited on day 0 (day of enrolment), 
1, 4, 10, and 28. At each visit, the study team (study 
supervisor and MCH staﬀ ) collected mortality and 
morbidity information on the baby from the mother or 
caretaker and examined the cord for redness, pus, 
swelling, and foul odour, and collected baseline data 
and demographic characteristics on the day of 
enrolment. Redness was categorised into four grades 
(none, mild, moderate, or severe). Mild redness was 
deﬁ ned as restricted to the cord stump only; moderate 
as less than 2 cm extension onto the abdominal skin at 
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the base of the cord stump; and severe as spreading 
noticeably (>2 cm) outward from the base of the stump. 
If infection was suspected, the supervisor informed the 
district in charge, the district in charge then visited the 
household and examined the baby, took a photograph 
of the cord, and referred the mother to the nearest 
hospital if the cord was infected. MCH staﬀ  and the 
study supervisor revisited the household on day 28 to 
collect information regarding morbidity and hospital 
admission, and collected and reported the mortality 
information in cases of death. Cord infection signs 
recorded during multiple visits for all infants were 
combined and assessed for positive status according to 
the omphalitis deﬁ nitions.
An electronic data capture system based on a netbook 
(small laptop) was used for collection of data. Each 
supervisor was provided with a netbook with the data 
collection software and pre-installed data uploading and 
backup plugin. Data from all netbook computers was 
backed up at the end of the day with universal serial bus 
(USB) drives, which were transported back to the central 
oﬃ  ce (Public Health Laboratory Ivo de Carneri) the same 
evening and data downloaded to the central database 
server. The updated server database was uploaded to the 
same USB drive. The database in each netbook was 
replaced by the updated server database from the USB 
drive each morning before the start of work to ensure 
data consistency and integrity. We designed a robust data 
management system to help the teams plan their 
activities and quality control.
Outcomes
The primary outcome for this study was mortality until 
day 28. The secondary outcome was omphalitis occurring 
any time during ﬁ rst 10 days after birth. Any adverse 
events related to chlorhexidine use were noted. 
Statistical analysis
During study design, the sample size was calculated on 
the assumption that the neonatal mortality rate in Pemba 
was 31 per 1000 livebirths and with a target of a 25% 
reduction in mortality. With 90% power and 5% two-
sided type I error, and accounting for a 20% loss of deaths 
(due to death occurring before the intervention was 
started, loss to follow-up, or refusals), the sample size 
required was 11 990 per group. The DSMB did two 
interim analyses in June, 2012, with a third of all enrolled 
newborn babies, and in June, 2014, with two-thirds of all 
enrolled babies. Because actual mortality rates were 
substantially lower than our original assumption, the 
DSMB recommended (in November, 2012) that the 
required sample size for the primary outcome of 
mortality with 80% power be 30 000 per group. Based on 
the DSMB’s recommendation and after approvals from 
institutional review boards, the placebo group of wet cord 
care was discontinued from Feb 20, 2013, onwards, to 
allow data from Pemba to be combined with that in 
Zambia,18 which had chlorhexidine and dry cord care 
groups only. This decision was taken to provide a sample 
of reasonable power to assess the eﬀ ect of chlorhexidine 
on neonatal mortality in sub-Saharan Africa. The study 
strategy did not change between phase 1 and phase 2.
To assess the eﬀ ect of the intervention on mortality 
and omphalitis, intention-to-treat analyses included all 
enrolled babies. For babies whose families had moved 
out of the area or withdrawn from the study, data up until 
the date of censorship were included. We analysed 
survival of newborn babies in the ﬁ rst 28 days with 
Poisson regression models with the chlorhexidine group 
as the independent variable, using Stata (version 13). We 
used Cox survival regression models to reconﬁ rm 
these results. Mortality was expressed as deaths 
per 1000 enrolled livebirths. Mortality outcomes were 
estimated overall, and stratiﬁ ed by place of birth 
(community or hospital), sex, ﬁ rst contact within 12 h, 
and birthweight. For births in hospital, day of enrolment 
was considered as a cluster; Poisson regression, with day 
of enrolment as the cluster variable, was done to adjust 
for the clustering eﬀ ect. We assessed the estimated 
diﬀ erence in treatment eﬀ ect between hospital and 
community births by Mantel-Cox comparison between 
subgroups, estimating χ² for unequal relative rates (eﬀ ect 
modiﬁ cation) and its p value (STMC procedure in Stata). 
Additionally, we built a regression model with death as 
the dependent variable and intervention group, place of 
birth, and interaction term (intervention × place of birth) 
as independent variables.
Risk estimates from both Pemba and Zambia were 
combined using the metan command in Stata. Primary 
data from both the studies were pooled and analysed 
using a Poisson regression model adjusting for the 
clustering eﬀ ect (cluster-id as cluster variable in Zambia; 
day of enrolment for hospital births and study-id for 
community births in Pemba).
The trial is registered with ClinicalTrials.gov, number 
NCT01528852.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between May 19, 2011, and Aug 31, 2014, 47 545 births 
were identiﬁ ed in the study area, from which 
44 232 newborn babies were enrolled into the study 
(ﬁ gure). 36 911 newborn babies were assigned to the 
chlorhexidine and dry cord care groups in phases 1 and 2. 
Of the 22 097 babies enrolled during phase 1, 7484 (34%) 
were assigned to the dry cord care group and 7292 (33%) 
were assigned to the chlorhexidine group, with the 
remainder assigned to the placebo group, which was not 
Articles
www.thelancet.com/lancetgh   Vol 4   November 2016 e841
analysed further in this main outcomes study. Of the 
22 135 babies enrolled during phase 2, 11 412 (52%) were 
in the dry cord care group and 10 723 (48%) were in the 
chlorhexidine group. There were no baseline diﬀ erences 
in neonatal or parental demographic characteristics 
between the two groups (table 1). 19 426 (52·6%) of 
all 36 911 births took place in a hospital (table 1). 
16 896 (93·8%) of 18 015 babies in the chlorhexidine 
group and 17 577 (93·0%) of 18 896 in the dry cord care 
group were contacted within 24 h of birth (table 2); 
17 468 (97·0%) of 18 015 neonates in the chlorhexidine 
group were available for complete follow-up (28 days) 
compared with 18 384 (97·3%) of 18 896 neonates in the 
dry cord care group. 36 162 (98·0%) of babies attended all 
the planned visits (table 2).
Overall, neonatal deaths were reported in 221 (1·2%) 
babies in the dry cord care group compared with 
189 (1·0%) babies in the chlorhexidine group. The risk of 
mortality after enrolment was not signiﬁ cantly diﬀ erent 
between the two groups (table 3). The risk of mortality did 
not diﬀ er by place of birth (relative risk [RR] 0·90, 95% CI 
0·74–1·10; p=0·32; both treatment groups combined). 
Additionally, the model using intervention group, place of 
birth, and an interaction term between intervention and 
place of birth as independent variables calculated an RR 
of 0·97 (95% CI 0·65–1·45) for the interaction term and 
RR of 0·92 (0·67–1·27) for the intervention group. The 
sex of the baby and time of ﬁ rst application did not have a 
diﬀ erential eﬀ ect on mortality. There were no signiﬁ cant 
diﬀ erences in the eﬀ ect of chlorhexidine on early (ﬁ rst 
7 days) or late (8–27 days) neonatal mortality (early 
mortality occurred in 140 [0·8%] of 18 015 babies in the 
chlorhexidine group vs 172 [0·9%] of 18 896 babies in the 
dry cord care group; late mortality occurred in 49 [0·3%] 
of 18 015 vs 49 [0·3%] of 18 896 babies).
Combination of the results from Pemba and Zambia 
(meta-analysis using random eﬀ ects model) gave an RR 
of 0·99 (95% CI 0·80–1·23) for overall mortality risk by 
day 28 between chlorhexidine and dry cord care, whereas 
the combination of individual patient data (pooled 
analysis) gave an RR of 1·02 (0·86–1·20).
Babies in the chlorhexidine group had a lower risk of 
omphalitis with severe redness and pus (94% lower, 
95% CI 74–98%) and of any redness or pus (35% lower, 
30–39%) than did those in the dry cord care group 
(table 4).
Discussion
Within the constraints of reduced power caused by lower 
rates of mortality than expected in both treatment groups, 
we did not observe a signiﬁ cant reduction in neonatal 
mortality in the chlorhexidine group compared with the 
Figure: Trial proﬁ le
47 545 births screened 1313 ineligible 
969 stillbirths
220 died before contact
71 sick babies
53 non-residents
46 232 babies eligible
2000 refusals
44 232 babies enrolled
Assessed in future analyses
22 135 enrolments after 
Feb 20, 2013 
(phase 2)
22 097 enrolments until 
Feb 20, 2013 
(phase 1)
7321 babies randomly 
assigned to placebo
7292 babies randomly 
assigned to 
chlorhexidine
7484 babies randomly 
assigned to dry 
cord care
10 723 babies randomly 
assigned to 
chlorhexidine
11 412 babies randomly 
assigned to dry 
cord care
18 015 included in 
chlorhexidine group 
in main analysis
18 896 included in dry cord 
care group in main 
analysis
17 467 completed 28 day 
follow-up
18 383 completed 28 day 
follow-up
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dry cord care group, or when we combined these results 
from Pemba, Tanzania, with those from Zambia. 
Additionally, the 10% lower mortality rate reported in the 
chlorhexidine group was much smaller than that 
hypothesised based on the ﬁ ndings of the Asian trials.11
However, our ﬁ ndings did show that application of 
chlorhexidine signiﬁ cantly reduced the prevalence of 
omphalitis when compared with dry cord care. The risk 
of omphalitis was reduced by 24–39% for most grades 
of infection and was reduced by 94% for omphalitis when 
deﬁ ned as severe redness with pus. These ﬁ ndings are 
consistent with those from earlier trials in Nepal,7 
Pakistan,8 and Bangladesh.11 Similar to our ﬁ ndings, the 
risk of cord infection in Nepal was reduced by 32–75% for 
diﬀ erent grades of infection in the chlorhexidine 
cleansing group, and in Bangladesh, newborn babies who 
had 7 days of chlorhexidine application were at a lower 
risk of any redness in the umbilical stump or pus than 
babies who had 1 day of chlorhexidine application. Results 
from the trial in Pakistan also showed a lower risk of 
omphalitis of any grade in babies in the chlorhexidine 
group than babies in the dry cord care group.
The umbilical cord stump of a newborn baby is a prime 
site of bacterial colonisation. Infection of the stump—
omphalitis—poses a serious threat to the newborn baby 
and has been suggested to play an important role in 
systemic infection and mortality risk. The patency of the 
umbilical blood vessels in the ﬁ rst few days of life is 
known to provide access for pathogens to enter the blood 
stream even in the absence of omphalitis.6,21,22 Hence, one 
possible explanation for the disparity in the eﬀ ects of 
chlorhexidine between omphalitis and mortality could be 
the occurrence of sepsis without omphalitis. Sepsis in 
the absence of omphalitis can occur when the host 
immunity does not limit the infection to the umbilical 
stump, causing direct systemic infection without eliciting 
localised signs of omphalitis. Application of chlorhexidine 
on the cord stump might reduce the risk of local cord 
infection, but not prevent the pathogens from entering 
into the bloodstream through patent umbilical vessels, 
leading to sepsis and death.23 Application of chlorhexidine 
is known to substantially delay cord separation. If the 
delay in cord separation perpetuates the risk of exposing 
the vessels to bacterial contamination,24 it might have 
been responsible for the diﬀ erences between 1 day versus 
7 days of chlorhexidine application in the Bangladesh 
study and the inconsistency between omphalitis and 
mortality results in our study. Any risk related to delayed 
cord separation needs further investigation.
Before the start of the study, the neonatal mortality 
rate in sub-Saharan Africa was reported to be higher 
(31 deaths per 1000 livebirths) than in Pakistan (29 per 
1000 livebirths),8 Bangladesh (24 per 1000 livebirths), and 
Nepal (23 per 1000 livebirths).4 However, mortality rates in 
Africa have changed substantially in the past decade. The 
observed per-protocol mortality rates in the chlorhexidine 
and dry cord care groups in our study (10·5 and 11·7 per 
1000 livebirths, respectively), were much lower than we 
estimated. These rates were also lower than reported in 
studies in Bangladesh (22·5 and 28·3 deaths per 
1000 livebirths, respectively) and Nepal (14·6 and 19·3 per 
1000 livebirths, respectively). The low overall mortality 
rates in our study could be attributed to a general time 
trend as indicated by decline of neonatal mortality 
rate from 31 to 25 per 1000 livebirths in 201019 and 
19 per 1000 livebirths in 2015.1 The mortality rates recorded 
in this study could also have been aﬀ ected by increased 
sensitisation of the mothers and other family members of 
cord care hygiene during the formative phase of the study, 
Chlorhexidine 
(n=18 015)
Dry cord care 
(n=18 896)
Parental occupation
Father: ﬁ shing or farming 6440 (35·7%) 6728 (35·7%)
Mother: housewife 12 422 (69·0%) 13 019 (68·9%)
Parental literacy
Paternal illiteracy 3472 (19·3%) 3487 (18·5%)
Maternal illiteracy 4916 (27·3%) 5012 (26·5%)
Household ownership 15 692 (87·1%) 16 383 (86·7%)
Maternal parity
First or second child 3963 (22·0%) 4365 (23·1%)
Third or fourth child 5260 (29·2%) 5537 (29·3%)
Fifth or higher 8791 (48·8%) 8994 (47·6%)
Single or multiple birth
Single 17 384 (96·5%) 18 178 (96·2%)
Twins 631 (3·5%) 718 (3·8%)
Sex of neonate
Male 9201 (51·1%) 9589 (50·7%)
Female 8814 (48·9%) 9307 (49·3%)
Birthplace of neonate
Hospital 9272 (51·5%) 10 154 (53·7%)
Community 8742 (48·5%) 8743 (46·3%)
Data are n (%). 
 Table 1: Baseline demographic neonatal, maternal, and household 
characteristics
Chlorhexidine 
(n=18 015)
Dry cord care 
(n=18 896)
Day 0 visit 18 015 (100%) 18 896 (100%)
Day 1 visit 17 820 (98·9%) 18 742 (99·2%)
Day 4 visit 17 702 (98·3%) 18 611 (98·5%)
Day 10 visit 17 620 (97·8%) 18 542 (98·1%)
All planned visits made 17 620 (97·8%) 18 542 (98·1%)
Excluding deaths 17 580 (98·6%) 18 504 (99·1%)
Timing of cord intervention
Within 12 h 9721 (54·0%) 10 008 (53·4%)
13–24 h 7175 (39·8%) 7569 (40·1%)
>24 h 1119 (6·2%) 1239 (6·5%)
Data are n (%).
 Table 2: Coverage and timing of intervention or visit
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and the prevalent cord care practices in this region. 
A study25 done during the formative phase of this trial 
revealed that dry cord care is a well understood and 
practised concept in Pemba. Therefore, dry cord care 
might already have been better practised in this setting 
than in the Asian study populations. However, the eﬀ ects 
on omphalitis would suggest that there was still a 
substantial risk of contamination of the cord stump in 
Pemba and any practice related to cord care would be 
unlikely to aﬀ ect neonatal mortality. Even though the 
results from three trials of chlorhexidine for cord care 
show reduction of neonatal infections and deaths, these 
studies have not established the ideal timing and duration 
of chlorhexidine application.26 With the conﬂ icting results 
of 1 day and 7 day application of chlorhexidine in the trial 
in Bangladesh, further investigation is needed to 
understand the eﬀ ects in Asia and sub-Saharan Africa.
By contrast with the previous trials in south Asia,26 
which predominantly enrolled home births (>90%) and 
were cluster randomised trials with potential for baseline 
diﬀ erences, the strengths of our study are that this trial is 
an individually randomised controlled trial with a large 
sample size; we enrolled children both from community 
births (47%) and hospital births (53%); the proportion of 
babies contacted within 24 h was higher in our study, 
with 93% of ﬁ rst contacts made within 24 h in both 
groups, than in Bangladesh (86–88%) and in Nepal 
(62–64%), which should have improved the impact of 
chlorhexidine in our trial; and more than 95% of the 
screened and eligible newborn babies were included in 
the ﬁ nal analysis, thereby reducing selection bias.
A weakness of our study is that the independent power 
of the study is low because the observed mortality rates 
were lower than expected. However, along with a 
concomitant trial in Zambia,18 we present important ﬁ rst 
evidence that chlorhexidine application on the umbilical 
cord has no eﬀ ect on mortality in low-resource settings 
in sub-Saharan Africa. The study results and combined 
analysis suggest that chlorhexidine does not have a 
substantial impact on mortality in both settings.
The study area is comparable to other African countries 
in terms of limited resources, low rates of skilled 
attendance at birth, and unhygienic cord care practices.7,8,11,18 
In this study, we did not observe any diﬀ erences in the 
eﬀ ect of chlorhexidine on omphalitis or mortality between 
hospital births and community births. This argues against 
a lack of impact compared with Asian studies being due to 
higher hospital births in our setting.
The ﬁ ndings in our study suggest that use of 
chlorhexidine for the reduction of omphalitis is justiﬁ ed, 
but in an African setting there is insuﬃ  cient evidence to 
promote this intervention to reduce neonatal mortality. 
In most African settings, mortality estimates are much 
lower than those reported by Demographic and Health 
Surveys, especially where prospective data have been 
collected. The low neonatal mortality rate observed in 
this trial (17 per 1000 livebirths [including deaths before 
randomisation] compared with 25 per 1000 livebirths 
reported by the Tanzania Demographic Health Survey19) 
is consistent with the situation in most African settings. 
A pooled analysis of the two African trials combined with 
the three Asia trials needs to be undertaken to inform 
policy. Such an analysis will require careful description 
of the diﬀ erent contexts (eg, community vs hospital 
delivery, low vs high neonatal mortality rate, and diﬀ erent 
cultural practices) and attention to weighting of the 
studies in the meta-analysis, quality scoring, and other 
related statistical details. This meta-analysis should 
be done under the coordination of WHO with the 
involvement of independent consultants in addition to 
the investigators.
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Chlorhexidine 
(n=18 015)
Dry cord care 
(n=18 896)
Relative risk 
(95% CI)
p value
Deaths Deaths per 
1000 
livebirths
Deaths Deaths per 
1000 
livebirths
Overall 189 10·5 221 11·7 0·90 (0·74–1·09) 0·27
Place of birth
Hospital 116 12·5 142 14·0 0·89 0·70–1·14) 0·37
Community 73 8·4 79 9·0 0·92 (0·67–1·27) 0·63
Sex
Male 107 11·6 123 12·8 0·91 (0·71–1·11) 0·46
Female 82 9·3 98 10·5 0·88 (0·66–1·18) 0·41
First contact
≤12 h 111 11·4 123 12·2 0·90 (0·69–1·16) 0·42
≥12 h 78 9·4 97 11·0 0·84 (0·62–1·13) 0·24
Birthweight 
Low birthweight 29 66·7 32 67·1 0·99 (0·59–1·67) 0·98
Normal birthweight 56 8·1 54 7·2 1·14 (0·78–1·65) 0·50
Table 3: Neonatal mortality in the intention-to-treat population
Chlorhexidine 
(n=18 015)
Dry cord care 
(n=18 896)
Relative risk 
(95% CI)
p value
N n per 1000 
livebirths 
N n per 1000 
livebirths 
Any redness or pus 1413 78·4 2183 115·5 0·65 (0·61–0·70) <0·0001
Any redness without pus 1051 58·4 1427 75·5 0·76 (0·70–0·82) <0·0001
Moderate redness with pus 
or severe redness
166 9·2 286 15·1 0·61 (0·50–0·73) <0·0001
Severe redness with pus 2 0·1 33 1·8 0·06 (0·02–0·26) 0·0001
 Table 4: Omphalitis in the intention-to-treat population
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